TY - JOUR
T1 - Induction of human regulatory innate lymphoid cells from group 2 innate lymphoid cells by retinoic acid
AU - Morita, Hideaki
AU - Kubo, Terufumi
AU - Rückert, Beate
AU - Ravindran, Avinash
AU - Soyka, Michael B.
AU - Rinaldi, Arturo Ottavio
AU - Sugita, Kazunari
AU - Wawrzyniak, Marcin
AU - Wawrzyniak, Paulina
AU - Motomura, Kenichiro
AU - Tamari, Masato
AU - Orimo, Keisuke
AU - Okada, Naoko
AU - Arae, Ken
AU - Saito, Kyoko
AU - Altunbulakli, Can
AU - Castro-Giner, Francesc
AU - Tan, Ge
AU - Neumann, Avidan
AU - Sudo, Katsuko
AU - O'Mahony, Liam
AU - Honda, Kenya
AU - Nakae, Susumu
AU - Saito, Hirohisa
AU - Mjösberg, Jenny
AU - Nilsson, Gunnar
AU - Matsumoto, Kenji
AU - Akdis, Mübeccel
AU - Akdis, Cezmi A.
N1 - Funding Information:
Supported by Swiss National Science Foundation grants 310030_156823 and 320030_140772 (to C.A.), Grants-in-Aid for Young Scientists (B; to H.M.), MSD Life Science Foundation , Public Interest Incorporated Foundation (to H.M.), a Grant of National Center for Child Health and Development (#29-2; to H.M.), and Precursory Research for Embryonic Science and Technology,Japan Science and Technology Agency (to S.N.), Heart and Lung Foundation , Swedish Research Council , and the ChAMP (Centre for Allergy Research Highlights Asthma Markers of Phenotype) consortium funded by the Swedish Foundation for Strategic Research , the Karolinska Institutet , and AstraZeneca & Science for Life Laboratory Joint Research Collaboration (to J.M. and G.N.).
Funding Information:
Supported by Swiss National Science Foundation grants 310030_156823 and 320030_140772 (to C.A.), Grants-in-Aid for Young Scientists (B; to H.M.), MSD Life Science Foundation, Public Interest Incorporated Foundation (to H.M.), a Grant of National Center for Child Health and Development (#29-2; to H.M.), and Precursory Research for Embryonic Science and Technology,Japan Science and Technology Agency (to S.N.), Heart and Lung Foundation, Swedish Research Council, and the ChAMP (Centre for Allergy Research Highlights Asthma Markers of Phenotype) consortium funded by the Swedish Foundation for Strategic Research, the Karolinska Institutet, and AstraZeneca & Science for Life Laboratory Joint Research Collaboration (to J.M. and G.N.).Disclosure of potential conflict of interest: C. A. Akdis has consultant arrangements with Actellion, Aventis, Allergopharma and Circacia and has received grants from Novartis. H. Saito has received personal fees from Shiseido and AstraZeneca. K. Matsumoto has received speakers' bureaus from Merck Sharp and Dohme, AstraZeneca, Kyorin Pharmaceutical, Maruho, and Chugai Pharmaceutical. The rest of the authors declare that they have no relevant conflicts of interest. Supported by Swiss National Science Foundation grants 310030_156823 and 320030_140772 (to C.A.), Grants-in-Aid for Young Scientists (B; to H.M.), MSD Life Science Foundation, Public Interest Incorporated Foundation (to H.M.), a Grant of National Center for Child Health and Development (#29-2; to H.M.), and Precursory Research for Embryonic Science and Technology,Japan Science and Technology Agency (to S.N.), Heart and Lung Foundation, Swedish Research Council, and the ChAMP (Centre for Allergy Research Highlights Asthma Markers of Phenotype) consortium funded by the Swedish Foundation for Strategic Research, the Karolinska Institutet, and AstraZeneca & Science for Life Laboratory Joint Research Collaboration (to J.M. and G.N.). Disclosure of potential conflict of interest: C. A. Akdis has consultant arrangements with Actellion, Aventis, Allergopharma and Circacia and has received grants from Novartis. H. Saito has received personal fees from Shiseido and AstraZeneca. K. Matsumoto has received speakers' bureaus from Merck Sharp and Dohme, AstraZeneca, Kyorin Pharmaceutical, Maruho, and Chugai Pharmaceutical. The rest of the authors declare that they have no relevant conflicts of interest. We thank the members of SIAF (Dr Willem van de Veen, Mr Oliver Wirz, Ms Anna Globinska, Dr Barbara Stanic, Dr Shuo Li, and Dr Milena Sokolowska) and the members of NCCHD (Ms Masako Fujiwara, Ms Yoshiko Shimamoto, Ms Tamiko Sasaki, Mr Nobuyuki Watanabe, Dr Mariko Hara, Dr Akio Matsuda, and Ms Kazue Takeda) for their skilled technical assistance. We also thank the members of IMS (Dr Ayako Takamori, Dr Eri Shimura, and Ms Sachiko Yamaguchi) for their invaluable technical assistance. We thank Dr Jesper Säfholm and Dr Mamdoh-AI-Ameri on behalf of ChAMP for the human lung tissue. Supported by Swiss National Science Foundation grants 310030_156823 and 320030_140772 (to C.A.), Grants-in-Aid for Young Scientists (B; to H.M.), MSD Life Science Foundation, Public Interest Incorporated Foundation (to H.M.), a Grant of National Center for Child Health and Development (#29-2; to H.M.), and Precursory Research for Embryonic Science and Technology,Japan Science and Technology Agency (to S.N.), Heart and Lung Foundation, Swedish Research Council, and the ChAMP (Centre for Allergy Research Highlights Asthma Markers of Phenotype) consortium funded by the Swedish Foundation for Strategic Research, the Karolinska Institutet, and AstraZeneca & Science for Life Laboratory Joint Research Collaboration (to J.M. and G.N.). Disclosure of potential conflict of interest: C. A. Akdis has consultant arrangements with Actellion, Aventis, Allergopharma and Circacia and has received grants from Novartis. H. Saito has received personal fees from Shiseido and AstraZeneca. K. Matsumoto has received speakers' bureaus from Merck Sharp and Dohme, AstraZeneca, Kyorin Pharmaceutical, Maruho, and Chugai Pharmaceutical. The rest of the authors declare that they have no relevant conflicts of interest.
Funding Information:
Supported by Swiss National Science Foundation grants 310030_156823 and 320030_140772 (to C.A.), Grants-in-Aid for Young Scientists (B; to H.M.), MSD Life Science Foundation, Public Interest Incorporated Foundation (to H.M.), a Grant of National Center for Child Health and Development (#29-2; to H.M.), and Precursory Research for Embryonic Science and Technology,Japan Science and Technology Agency (to S.N.), Heart and Lung Foundation, Swedish Research Council, and the ChAMP (Centre for Allergy Research Highlights Asthma Markers of Phenotype) consortium funded by the Swedish Foundation for Strategic Research, the Karolinska Institutet, and AstraZeneca & Science for Life Laboratory Joint Research Collaboration (to J.M. and G.N.).Disclosure of potential conflict of interest: C. A. Akdis has consultant arrangements with Actellion, Aventis, Allergopharma and Circacia and has received grants from Novartis. H. Saito has received personal fees from Shiseido and AstraZeneca. K. Matsumoto has received speakers' bureaus from Merck Sharp and Dohme, AstraZeneca, Kyorin Pharmaceutical, Maruho, and Chugai Pharmaceutical. The rest of the authors declare that they have no relevant conflicts of interest.
Publisher Copyright:
© 2019 American Academy of Allergy, Asthma & Immunology
PY - 2019/6
Y1 - 2019/6
N2 - Background: Group 2 innate lymphoid cells (ILC2s) play critical roles in induction and exacerbation of allergic airway inflammation. Thus clarification of the mechanisms that underlie regulation of ILC2 activation has received significant attention. Although innate lymphoid cells are divided into 3 major subsets that mirror helper effector T-cell subsets, counterpart subsets of regulatory T cells have not been well characterized. Objective: We sought to determine the factors that induce regulatory innate lymphoid cells (ILCregs). Methods: IL-10+ ILCregs induced from ILC2s by using retinoic acid (RA) were analyzed with RNA-sequencing and flow cytometry. ILCregs were evaluated in human nasal tissue from healthy subjects and patients with chronic rhinosinusitis with nasal polyps and lung tissue from house dust mite– or saline-treated mice. Results: RA induced IL-10 secretion by human ILC2s but not type 2 cytokines. IL-10+ ILCregs, which were converted from ILC2s by means of RA stimulation, expressed a regulatory T cell–like signature with expression of IL-10, cytotoxic T lymphocyte–associated protein 4, and CD25, with downregulated effector type 2–related markers, such as chemoattractant receptor–homologous molecule on TH2 cells and ST2, and suppressed activation of CD4+ T cells and ILC2s. ILCregs were rarely detected in human nasal tissue from healthy subjects or lung tissue from saline-treated mice, but numbers were increased in nasal tissue from patients with chronic rhinosinusitis with nasal polyps and in lung tissue from house dust mite–treated mice. Enzymes for RA synthesis were upregulated in airway epithelial cells during type 2 inflammation in vivo and by IL-13 in vitro. Conclusion: We have identified a unique immune regulatory and anti-inflammatory pathway by which RA converts ILC2s to ILCregs. Interactions between airway epithelial cells and ILC2s play an important roles in the generation of ILCregs.
AB - Background: Group 2 innate lymphoid cells (ILC2s) play critical roles in induction and exacerbation of allergic airway inflammation. Thus clarification of the mechanisms that underlie regulation of ILC2 activation has received significant attention. Although innate lymphoid cells are divided into 3 major subsets that mirror helper effector T-cell subsets, counterpart subsets of regulatory T cells have not been well characterized. Objective: We sought to determine the factors that induce regulatory innate lymphoid cells (ILCregs). Methods: IL-10+ ILCregs induced from ILC2s by using retinoic acid (RA) were analyzed with RNA-sequencing and flow cytometry. ILCregs were evaluated in human nasal tissue from healthy subjects and patients with chronic rhinosinusitis with nasal polyps and lung tissue from house dust mite– or saline-treated mice. Results: RA induced IL-10 secretion by human ILC2s but not type 2 cytokines. IL-10+ ILCregs, which were converted from ILC2s by means of RA stimulation, expressed a regulatory T cell–like signature with expression of IL-10, cytotoxic T lymphocyte–associated protein 4, and CD25, with downregulated effector type 2–related markers, such as chemoattractant receptor–homologous molecule on TH2 cells and ST2, and suppressed activation of CD4+ T cells and ILC2s. ILCregs were rarely detected in human nasal tissue from healthy subjects or lung tissue from saline-treated mice, but numbers were increased in nasal tissue from patients with chronic rhinosinusitis with nasal polyps and in lung tissue from house dust mite–treated mice. Enzymes for RA synthesis were upregulated in airway epithelial cells during type 2 inflammation in vivo and by IL-13 in vitro. Conclusion: We have identified a unique immune regulatory and anti-inflammatory pathway by which RA converts ILC2s to ILCregs. Interactions between airway epithelial cells and ILC2s play an important roles in the generation of ILCregs.
KW - Group 2 innate lymphoid cells
KW - IL-33
KW - Regulatory innate lymphoid cells
KW - asthma
KW - chronic rhinosinusitis with nasal polyps
KW - cytotoxic T lymphocyte–associated protein 4
KW - retinoic acid
UR - http://www.scopus.com/inward/record.url?scp=85061691891&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061691891&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2018.12.1018
DO - 10.1016/j.jaci.2018.12.1018
M3 - Article
C2 - 30682454
AN - SCOPUS:85061691891
SN - 0091-6749
VL - 143
SP - 2190-2201.e9
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 6
ER -